Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$11.02 USD
-0.15 (-1.34%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $11.06 +0.04 (0.36%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MLYS 11.02 -0.15(-1.34%)
Will MLYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for MLYS
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares
Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors